AR067184A1 - Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica - Google Patents
Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceuticaInfo
- Publication number
- AR067184A1 AR067184A1 ARP080102760A ARP080102760A AR067184A1 AR 067184 A1 AR067184 A1 AR 067184A1 AR P080102760 A ARP080102760 A AR P080102760A AR P080102760 A ARP080102760 A AR P080102760A AR 067184 A1 AR067184 A1 AR 067184A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- pharmaceutical use
- acceptable
- oxo
- chloro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: El uso de ácido 6-(3-cloro-2-fluorbencil)-1-[(2S)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxílico, o de una sal aceptable para uso farmacéutico de dicho compuesto; lopinavir, o una de sus sales aceptables para uso farmacéutico; y un compuesto que inhibe el citocromo P-450, para el tratamiento profiláctico o terapéutico de una infeccion viral en un ser humano. Reivindicacion 21: Una composicion farmacéutica que comprende ácido 6-(3-cloro-2-fluorbencil)-1-[(2S)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxílico, o una de sus sales aceptables para uso farmacéutico; lopinavir, o una sal aceptable para uso farmacéutico de dicho compuesto; y un portador o diluyente farmacéuticamente aceptable. Reivindicacion 26: La composicion de cualquiera de las reivindicaciones 21-25, que además comprende 100 +- 50 mg de ritonavir, o de una sal aceptable para uso farmacéutico de dicho compuesto. Reivindicacion 55: El uso de lopinavir, o una de sus sales aceptables para uso farmacéutico, en combinacion con un compuesto que inhibe el citocromo P-450, o una de sus sales aceptables para uso farmacéutico, a fin de preparar un medicamento util para mejorar la farmacocinética de ácido 6-(3-cloro-2-fluorbencil)-1-[(2S)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxílico, o de una sal aceptable para uso farmacéutico de dicho compuesto, luego de la administracion a un ser humano. Reivindicacion 57: Un agente antiviral que comprende: (a) ácido 6-(3-cloro-2-fluorbencil)-1-[(2S)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4- dihidroquinolina-3-carboxílico, o una sal aceptable para uso farmacéutico de dicho compuesto; (b) lopinavir, o una de sus sales aceptables para uso farmacéutico; y (c) un compuesto que inhibe el citocromo P-450; para el uso en combinacion en el tratamiento profiláctico o terapéutico de una infeccion viral en un ser humano. Reivindicacion 59: Un compuesto acido 6-(3-cloro-2-fluorbencil)-1-[(2S)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxílico, o una sal aceptable para uso farmacéutico de dicho compuesto, que se usa en combinacion con lopinavir, o una de sus sales aceptables para uso farmacéutico, y con un compuesto que inhibe el citocromo P-450, en el tratamiento profiláctico o terapéutico de una infeccion viral en un ser humano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94732507P | 2007-06-29 | 2007-06-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR067184A1 true AR067184A1 (es) | 2009-09-30 |
Family
ID=39817166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080102760A AR067184A1 (es) | 2007-06-29 | 2008-06-26 | Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20110009411A1 (es) |
| EP (1) | EP2167089A1 (es) |
| JP (3) | JP5547067B2 (es) |
| KR (1) | KR20100028656A (es) |
| CN (2) | CN101743004A (es) |
| AP (1) | AP2490A (es) |
| AR (1) | AR067184A1 (es) |
| AU (1) | AU2008270634B2 (es) |
| BR (1) | BRPI0813955A2 (es) |
| CA (1) | CA2691736A1 (es) |
| CO (1) | CO6251236A2 (es) |
| EA (1) | EA200971096A1 (es) |
| EC (1) | ECSP109889A (es) |
| IL (1) | IL202745A0 (es) |
| MX (1) | MX2009013828A (es) |
| NZ (1) | NZ582089A (es) |
| SG (1) | SG182228A1 (es) |
| TW (1) | TW200916103A (es) |
| UA (1) | UA103881C2 (es) |
| WO (1) | WO2009006203A1 (es) |
| ZA (1) | ZA201000468B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG170795A1 (en) * | 2005-12-30 | 2011-05-30 | Gilead Sciences Inc | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| EP2049506B2 (en) | 2006-07-07 | 2024-05-08 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| AR063710A1 (es) | 2006-09-12 | 2009-02-11 | Gilead Sciences Inc | Proceso para la preparacion de acido 6-(3-cloro-2-fluorbencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolon-3-carboxilico como inhibidores de integrasa del hiv e intermediarios de sintesis del mismo y composiciones que lo comprenden. |
| PT2487163T (pt) * | 2007-02-23 | 2016-11-21 | Gilead Sciences Inc | Moduladores de propriedades farmacocinéticas de agentes terapêuticos |
| AU2008270630B2 (en) * | 2007-06-29 | 2014-01-16 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
| AR068403A1 (es) | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| MX2010011963A (es) | 2008-05-02 | 2010-12-06 | Gilead Sciences Inc | Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico. |
| CN102917695A (zh) * | 2010-04-09 | 2013-02-06 | 百时美施贵宝公司 | 具有改进的pH效应的阿扎那韦硫酸盐制剂 |
| WO2012088178A1 (en) * | 2010-12-21 | 2012-06-28 | Gilead Sciences, Inc. | Inhibitors of cytochrome p450 (cyp3a4) |
| CA2856722C (en) | 2011-11-30 | 2022-11-22 | Emory University | Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections |
| WO2013130766A1 (en) * | 2012-03-01 | 2013-09-06 | Gilead Sciences, Inc. | Spray dried formulations |
| BR112015002275A2 (pt) | 2012-08-03 | 2017-07-04 | Gilead Sciences Inc | processos e intermediários para a preparação de inibidores da integrase |
| UY35213A (es) | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Compuestos del tipo de las carbamilpiridonas policíclicas y su uso farmaceutico |
| AU2014286993B2 (en) | 2013-07-12 | 2018-10-25 | Gilead Sciences, Inc. | Polycyclic-carbamoylpyridone compounds and their use for the treatment of HIV infections |
| NO2865735T3 (es) | 2013-07-12 | 2018-07-21 | ||
| NO2717902T3 (es) | 2014-06-20 | 2018-06-23 | ||
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| TWI738321B (zh) | 2014-12-23 | 2021-09-01 | 美商基利科學股份有限公司 | 多環胺甲醯基吡啶酮化合物及其醫藥用途 |
| RS62434B1 (sr) | 2014-12-26 | 2021-11-30 | Univ Emory | Antivirusni n4-hidroksicitidin derivati |
| NZ735575A (en) | 2015-04-02 | 2018-11-30 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| KR102626210B1 (ko) | 2017-12-07 | 2024-01-18 | 에모리 유니버시티 | N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5539122A (en) * | 1989-05-23 | 1996-07-23 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| GB8927913D0 (en) * | 1989-12-11 | 1990-02-14 | Hoffmann La Roche | Amino acid derivatives |
| US5413999A (en) * | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5484926A (en) * | 1993-10-07 | 1996-01-16 | Agouron Pharmaceuticals, Inc. | HIV protease inhibitors |
| US5914332A (en) * | 1995-12-13 | 1999-06-22 | Abbott Laboratories | Retroviral protease inhibiting compounds |
| US5849911A (en) * | 1996-04-22 | 1998-12-15 | Novartis Finance Corporation | Antivirally active heterocyclic azahexane derivatives |
| US6087383A (en) * | 1998-01-20 | 2000-07-11 | Bristol-Myers Squibb Company | Bisulfate salt of HIV protease inhibitor |
| EP1564210B9 (en) * | 2002-11-20 | 2010-03-31 | Japan Tobacco Inc. | 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors |
| US20060111933A1 (en) * | 2003-10-09 | 2006-05-25 | Steven Wheeler | Adaptive medical decision support system |
| MY134672A (en) * | 2004-05-20 | 2007-12-31 | Japan Tobacco Inc | Stable crystal of 4-oxoquinoline compound |
| JP4629104B2 (ja) * | 2004-05-21 | 2011-02-09 | 日本たばこ産業株式会社 | ４−オキソキノリン誘導体および抗ｈｉｖ剤を含む併用剤 |
| US20060058286A1 (en) * | 2004-09-16 | 2006-03-16 | Mark Krystal | Methods of treating HIV infection |
| US20090233964A1 (en) * | 2005-12-30 | 2009-09-17 | Gilead Sciences, Inc. | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| SG170795A1 (en) * | 2005-12-30 | 2011-05-30 | Gilead Sciences Inc | Methods for improving the pharmacokinetics of hiv integrase inhibitors |
| WO2007092802A1 (en) * | 2006-02-09 | 2007-08-16 | Boehringer Ingelheim International Gmbh | Method for treating hiv infection through co-administration of tipranavir and gs 9137 |
| EP2049506B2 (en) * | 2006-07-07 | 2024-05-08 | Gilead Sciences, Inc. | Modulators of pharmacokinetic properties of therapeutics |
| AR063710A1 (es) * | 2006-09-12 | 2009-02-11 | Gilead Sciences Inc | Proceso para la preparacion de acido 6-(3-cloro-2-fluorbencil)-1-[(s)-1-hidroximetil-2-metilpropil]-7-metoxi-4-oxo-1, 4-dihidroquinolon-3-carboxilico como inhibidores de integrasa del hiv e intermediarios de sintesis del mismo y composiciones que lo comprenden. |
| AU2008270630B2 (en) * | 2007-06-29 | 2014-01-16 | Gilead Sciences, Inc. | Therapeutic compositions and the use thereof |
| AR068403A1 (es) * | 2007-09-11 | 2009-11-18 | Gilead Sciences Inc | Proceso e intermediarios para la preparacion de inhibidores de integrasa |
| MX2010011963A (es) * | 2008-05-02 | 2010-12-06 | Gilead Sciences Inc | Uso de particulas trasportadoras solidas para mejorar la capacidad de procesamiento de un agente farmaceutico. |
| US20110000941A1 (en) * | 2009-07-06 | 2011-01-06 | Volk J Patrick | Apparatus and System for Carrying a Digital Media Player |
-
2008
- 2008-06-26 EA EA200971096A patent/EA200971096A1/ru unknown
- 2008-06-26 MX MX2009013828A patent/MX2009013828A/es not_active Application Discontinuation
- 2008-06-26 NZ NZ582089A patent/NZ582089A/xx not_active IP Right Cessation
- 2008-06-26 BR BRPI0813955A patent/BRPI0813955A2/pt not_active IP Right Cessation
- 2008-06-26 EP EP20080781024 patent/EP2167089A1/en not_active Withdrawn
- 2008-06-26 CA CA002691736A patent/CA2691736A1/en not_active Abandoned
- 2008-06-26 WO PCT/US2008/068351 patent/WO2009006203A1/en active Application Filing
- 2008-06-26 UA UAA200913904A patent/UA103881C2/ru unknown
- 2008-06-26 CN CN200880022821A patent/CN101743004A/zh active Pending
- 2008-06-26 JP JP2010515115A patent/JP5547067B2/ja not_active Expired - Fee Related
- 2008-06-26 CN CN2013101948825A patent/CN103356622A/zh active Pending
- 2008-06-26 KR KR1020107001984A patent/KR20100028656A/ko not_active Application Discontinuation
- 2008-06-26 AP AP2009005083A patent/AP2490A/xx active
- 2008-06-26 SG SG2012046926A patent/SG182228A1/en unknown
- 2008-06-26 AR ARP080102760A patent/AR067184A1/es not_active Application Discontinuation
- 2008-06-26 TW TW097123981A patent/TW200916103A/zh unknown
- 2008-06-26 AU AU2008270634A patent/AU2008270634B2/en not_active Ceased
- 2008-06-26 US US12/666,995 patent/US20110009411A1/en not_active Abandoned
- 2008-06-26 US US12/147,220 patent/US20090093482A1/en not_active Abandoned
-
2009
- 2009-12-15 IL IL202745A patent/IL202745A0/en unknown
- 2009-12-21 CO CO09146050A patent/CO6251236A2/es not_active Application Discontinuation
-
2010
- 2010-01-21 EC EC2010009889A patent/ECSP109889A/es unknown
- 2010-01-21 ZA ZA2010/00468A patent/ZA201000468B/en unknown
-
2013
- 2013-07-08 JP JP2013142320A patent/JP5769762B2/ja not_active Expired - Fee Related
-
2014
- 2014-05-19 US US14/281,790 patent/US20140343062A1/en not_active Abandoned
-
2015
- 2015-05-07 JP JP2015094705A patent/JP2015143277A/ja not_active Withdrawn
-
2016
- 2016-10-19 US US15/298,070 patent/US20170136000A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013199494A (ja) | 2013-10-03 |
| ECSP109889A (es) | 2010-03-31 |
| SG182228A1 (en) | 2012-07-30 |
| JP5547067B2 (ja) | 2014-07-09 |
| MX2009013828A (es) | 2010-03-10 |
| UA103881C2 (ru) | 2013-12-10 |
| CN101743004A (zh) | 2010-06-16 |
| TW200916103A (en) | 2009-04-16 |
| AU2008270634B2 (en) | 2014-01-16 |
| US20090093482A1 (en) | 2009-04-09 |
| CA2691736A1 (en) | 2009-01-08 |
| BRPI0813955A2 (pt) | 2017-05-09 |
| US20110009411A1 (en) | 2011-01-13 |
| CO6251236A2 (es) | 2011-02-21 |
| AU2008270634A1 (en) | 2009-01-08 |
| US20140343062A1 (en) | 2014-11-20 |
| EA200971096A1 (ru) | 2010-08-30 |
| KR20100028656A (ko) | 2010-03-12 |
| JP2015143277A (ja) | 2015-08-06 |
| CN103356622A (zh) | 2013-10-23 |
| AP2009005083A0 (en) | 2009-12-31 |
| AP2490A (en) | 2012-10-04 |
| US20170136000A1 (en) | 2017-05-18 |
| JP2010532373A (ja) | 2010-10-07 |
| EP2167089A1 (en) | 2010-03-31 |
| JP5769762B2 (ja) | 2015-08-26 |
| WO2009006203A1 (en) | 2009-01-08 |
| IL202745A0 (en) | 2010-06-30 |
| NZ582089A (en) | 2013-01-25 |
| ZA201000468B (en) | 2011-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR067184A1 (es) | Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica | |
| AR124134A2 (es) | Formulación de uso tópico para un inhibidor de jak | |
| FI3989972T3 (fi) | Glukakonin kaltainen peptidi 1 reseptorin agonistit | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| UY30819A1 (es) | Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones | |
| GT200600096A (es) | Composicion farmaceutica para el tratamiento del cancer | |
| PA8635201A1 (es) | Uso de derivados quinolina sustituidos para el tratamiento de enfermedades micobacterianas resistentes a los farmacos | |
| CO2018005842A2 (es) | Composición farmacéutica que comprende un potente inhibidor de urat 1 | |
| UY29085A1 (es) | Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes | |
| JP2013542247A5 (es) | ||
| RU2016122609A (ru) | Составы соединений азаиндола | |
| ES2916649T1 (es) | Composiciones y usos para el tratamiento de la esclerosis múltiple | |
| RS53209B (en) | PHARMACEUTICAL COMPOSITION FOR VIRAL HEPATITIS C PROTEASE INHIBITOR | |
| NO20080220L (no) | Formuleringer med hoy medikament belastning og doseringsformer | |
| JP2010530376A5 (es) | ||
| WO2008142572A3 (en) | Controlled release tablet formulation containing magnesium aluminometasilicate | |
| CL2011000798A1 (es) | Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular. | |
| EA200971087A1 (ru) | Фармацевтические композиции и способ лечения острой мании | |
| AR061668A1 (es) | Jarabes antihistaminicos, estables al almacenamiento, sin azucar | |
| NI201300008A (es) | El nuevo estable polietileno glicol conjugado de interferon alfa, representado por un isómero posicional | |
| NO20085414L (no) | Farmasoytiske preparater for vedvarende frigivelse av fenylefrin | |
| CL2010000524A1 (es) | Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales. | |
| AR073265A1 (es) | Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio | |
| AR064543A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| AR059838A1 (es) | Formulaciones para dosis estabilizantes de estatina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |